Literature DB >> 29053888

Epidemiological patterns of tick-borne encephalitis in Lithuania and clinical features in adults in the light of the high incidence in recent years: a retrospective study.

D Radzišauskienė1, K Žagminas2, L Ašoklienė2, A Jasionis3, R Mameniškienė3, A Ambrozaitis1, L Jančorienė1, D Jatužis3, I Petraitytė2, E Mockienė4.   

Abstract

BACKGROUND AND
PURPOSE: Lithuania is one of the countries with the highest incidence of tick-borne encephalitis (TBE) in Europe. The aim of this study was to describe the epidemiological patterns of TBE in Lithuania, and characterize clinical features in adults in the light of the high incidence in recent years.
METHODS: Surveillance data available on the website of the Centre for Communicable Diseases and AIDS of Lithuania were used to describe the epidemiological patterns of TBE. The retrospective study included 712 patients hospitalized in the Centre for Infectious Diseases and the Centre for Neurology of Vilnius University in the years 2005-2014.
RESULTS: Tick-borne encephalitis incidence rates have been increasing by 8.5% per year for the 45-year period from 1970 to 2014. The joinpoint model finds two joinpoints at 1991 and 1994, with a significant decrease of 8.4% per year (P < 0.05) prior to the joinpoint at 1991, and a rise of 195.2% afterwards. TBE presented with meningoencephalitis in 556 cases (81.3%). A total of 129 patients (18%) had a severe case of the disease. The most common neurological signs were ataxia (579, 81.3%), meningeal signs (474, 66.5%) and tremor (338, 47.5%). Limb paresis was observed in 6.3% of patients. Five patients (0.7%) died, and 544 patients (76.7%) were discharged with sequelae.
CONCLUSIONS: Intensified efforts in promoting TBE vaccination will be needed in the light of the high incidence and expanded spatial distribution. Significant prognostic factors for severe cases of the disease were age above 61 and delayed immune response of specific immunoglobulin G.
© 2017 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.

Entities:  

Keywords:  clinical forms; epidemiology; prognostic factors; tick-borne encephalitis

Mesh:

Year:  2017        PMID: 29053888      PMCID: PMC5814845          DOI: 10.1111/ene.13486

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


Introduction

Tick‐borne encephalitis (TBE) is the most important flavivirus infection of the nervous system. It is caused by the Far Eastern, Siberian and European subtype of tick‐borne encephalitis virus (TBEV). The European subtype comprises almost all known isolates from Europe. The virus persists in natural foci, where it circulates amongst both vertebrate hosts (mainly rodents) and the arthropod host (tick). In Ixodes ricinus in Europe, TBEV prevalence in unfed ticks varies between 0.1% and 5% 1. The European subtype is associated with milder disease, with mortality rates of 0.5%–2%, and severe neurological sequelae in up to 10% of patients 2. Treatment is based on symptomatic measures. However, TBE can be successfully prevented by a safe and highly effective vaccine 3. Tick‐borne encephalitis is a growing public health concern over recent decades in Europe 1, 4. The number of human cases of TBE in all endemic regions of Europe has increased by almost 400% in the last 30 years 2. The risk areas have spread, and new foci have been discovered. Lithuania is one of the countries with the highest incidence of TBE in Europe. According to the European Centre for Disease Prevention and Control (ECDC) surveillance data, the notification rate in 2014 was highest in Lithuania (12.0 cases per 100 000 population) 4. The aim of this study was to describe the epidemiological patterns of TBE in Lithuania, to characterize clinical features in adults in the light of the high incidence in recent years (2005–2014) and also to analyse the prognostic factors for severe cases of the disease.

Methods

Patients and study design

Surveillance data available on the website of the Centre for Communicable Diseases and AIDS of Lithuania (http://www.ulac.lt) were used to describe the epidemiological patterns of TBE in Lithuania. Population data for the calculation of rates were obtained from the Lithuanian Department of Statistics. The population as of 1 January of each year was used. Case rates are given per 100 000 population (the number of reported cases divided by the estimate of the population for that year multiplied by 100 000). A retrospective study was done to describe the clinical features of TBE in adults. The study included 712 patients diagnosed with TBE and hospitalized in the Centre for Infectious Diseases and the Centre for Neurology of the Medical Faculty of Vilnius University in the years 2005–2014. Cases were defined on the basis of laboratory results and documented clinical characteristics. The clinical criterion was a person with signs of central nervous system (CNS) involvement. The laboratory criteria were the presence of specific immunoglobulin M (IgM) and IgG in serum, or proven intrathecal synthesis of specific antibodies. The inclusion criterion was all patients with diagnosed TBE, age >18. The exclusion criteria were patients vaccinated against yellow fever or Japanese encephalitis, and patients infected with other flaviviruses. Confirmed cases were included for further analysis. EpiData (v.3.1.; The EpiData Association, Odense, Denmark) was used for data entry and data documentation.

Laboratory diagnosis

Tick‐borne encephalitis was laboratory confirmed by the demonstration of specific IgM and IgG activity by immunological tests with enzyme linked immunosorbent assay (ELISA) using a Virion/Serion (Wurzburg, Germany) kit. Some patients with TBE were diagnosed for possible Borrelia burgdorferi co‐infection. The ELISA kit was used for the demonstration of B. burgdorferi antibodies in sera. A diagnosis of neuroborreliosis was confirmed by the demonstration of specific IgM or IgG antibodies in cerebrospinal fluid (CSF). Virion/Serion kits were used for tick ‐ borne encephalitis virus and B. burgdorferi antibody detection from 2009.

Clinical classification

According to clinical presentation, all TBE cases were classified as meningitis, meningoencephalitis or meningoencephalomyelitis. Patients presenting signs of parenchymatous diseases of the brain such as focal neurological signs, seizures, decreased consciousness and delirium concomitant with CSF leucocytes >5 × 106/l were classified as having meningoencephalitis. Myelitic signs were defined as flaccid paresis of extremities. The clinical presentation of TBE was also classified as mild, moderate and severe. Severe disease was defined as disease with severe diffuse brain dysfunction, severe multifocal CNS symptoms and signs, and myelitic signs.

Statistical methods

Categorical data were analysed using the Pearson chi‐squared test. The Fisher exact test and the Wilcoxon rank sum test were used for continuous variables. P values of <0.05 were considered significant. Multiple binary logistic regression was used to assess prognostic factors for severe cases of TBE. Predictor variables of gender, age, comorbidities, delayed hospitalization, cytosis, delayed immune response and the presence of the first stage were included in the model. The GADM database of Global Administrative Areas was used for spatial analysis. Stata/IC 12.1 (StataCorp LP, Stata Statistical Software, College Station, TX, USA) software was used for analysis and to graph data onto maps. A joinpoint regression model 5 was used to investigate the pattern of TBE incidence rates. The response variable for the analysis of incidence was the natural logarithm of the reported incidence rates, and an independent variable was the reporting year from 1970 to 2014. The joinpoint regression program (v. 4.5.0.1.; Statistical Research and Applications Branch, National Cancer Institute, Bethesda, MD, USA) was used to analyse the data. A statistically significant joinpoint was P < 0.05. The Vilnius Regional Bioethics Committee approved this study in 2014 (No. 158200‐14‐742‐259).

Results

General characteristics of TBE in Lithuania

Incidence trends

Tick‐borne encephalitis was first reported in Lithuania in 1968, but serology was introduced in 1970. According to the results of the joinpoint analysis, it was determined that TBE incidence rates have been increasing by 8.5% per year for the 45‐year period 1970–2014. The joinpoint model finds two joinpoints at 1991 and 1994, with a significant decrease of 8.4% per year (P < 0.05) prior to the joinpoint at 1991 and a rise of 195.2% after. There was no significant change in the trend during the high incidence period in 2005–2014. Incidence increased annually by 7.4% (P = 0.1) (Fig. 1).
Figure 1

Annual incidence of tick‐borne encephalitis in Lithuania, 1970–2014 (n = 9370).

Annual incidence of tick‐borne encephalitis in Lithuania, 1970–2014 (n = 9370).

Spatial distribution

Tick‐borne encephalitis is present throughout Lithuania, but the northeast and central parts of the country are regarded as TBE foci. The incidence of TBE has significantly increased in five out of 10 counties in Lithuania in the last two decades.

Age and gender distribution

The highest notification rate of confirmed TBE was in the 45–54 years group (20.6 cases per 100 000 population), followed by 65–74‐ and 55–64‐year‐olds (19.7 and 19.2 cases per 100 000 population; Fig. 2). 53.3% of all cases were registered in the 45–74 age group during the period 2005–2014. During the period 2005–2014, 54.3% of cases were males, with an average notification rate of 15.5 per 100 000 population in males, and 11.2 per 100 000 population in females; the male‐to‐female ratio was 1.18:1.
Figure 2

Rates of confirmed reported TBE cases by age, 2005–2014.

Rates of confirmed reported TBE cases by age, 2005–2014.

Seasonality

Tick‐borne encephalitis is recorded almost throughout the year in Lithuania, but the disease is characterized by clearly expressed seasonality. During 2005–2014, TBE numbers of reported cases started to increase in April–May, peaked in October, and decreased for the rest of the year, with only a small number of cases reported in December and January (Fig. 3). During the 5 months of seasonal increase (June–October), 89.6% cases were recorded with TBE out of all cases.
Figure 3

Seasonal distribution of confirmed TBE cases in Lithuania, 2005–2014.

Seasonal distribution of confirmed TBE cases in Lithuania, 2005–2014.

A retrospective study of TBE cases hospitalized in the Centre for Infectious Diseases and the Centre for Neurology of the Faculty of Medicine, Vilnius University

Epidemiological and demographic data

A total of 460 (64%) patients noticed one or more tick bites (Table 1), and 92 (13%) patients had more than one tick bite (2–10). The highest number of hospitalized patients was in the years 2012 and 2013.
Table 1

Epidemiological, demographic data and the clinical course of tick‐borne encephalitis

Study characteristicValue, n (%)
Inhabitants of cities427 (60)
Receipt of tick bite/bites460 (64)
Milk‐borne infection49/625 (7.8)
Infected in living area223/528 (42.2)
Job‐related infection10/528 (1.9)
Incubation period (days)11.4 (2–41)
Biphasic course413 (58.1)
Duration of first stage, mean (min–max) (days)4.9 (1–19)
Interval between first and second stage, mean (min–max) (days)14.6 (3–100)
Patient's sex
Male387 (54)
Age, median (min–max) (years)51 (18–85)
Clinical form of illness
Meningitis66 (9.6)
Meningoencephalitis556 (81.3)
Meningoencephalomyelitis22 (3.2)
Encephalitis40 (5.8)
Symptoms and signs before hospitalization
Fever709 (99.6)
Headache647 (90.9)
Vertigo288 (40.4)
Nausea/vomiting214 (30.1)
Muscle pain44 (6.2)
Diarrhoea10 (1.4)
Neurological symptoms and signs229 (32.2)
Epidemiological, demographic data and the clinical course of tick‐borne encephalitis A total of 295 (41%) had pre‐existing conditions, the most common being arterial hypertension (161, 22.6%), coronary heart disease (58, 8.1%) and diabetes mellitus (27, 3.8%). A total of 22 patients (3%) had chronic CNS diseases; two women were pregnant; two women were 3 weeks to 6 months after delivery.

Clinical presentation

The mean duration of the first phase was 4.9 days, according to available data on 322 patients (Table 1). The duration of the asymptomatic period was not related to disease severity (P < 0.05). The mean time from onset of illness to hospitalization was 5.8 days. The median length of hospital stay was 11.9 days (minimum 1 day, maximum 129 days). The most frequent clinical form was meningoencephalitis (556/684, 81.3%) (Table 1). A total of 16 patients presented peripheral nervous system involvement (poliradiculitis or polineuritis). Meningitis was more common in the group of young patients (18–30 years); myelitis was more common in older patients (P < 0.001). The majority of patients (489, 69%) had a moderate case of the disease. A total of 129 patients (18%) had a severe case of the disease. A total of 35/88 (39.8%) had severe disease in the age group above 70 years, versus 13/111 (11.7%) in the 18–29 years group (P < 0.01). The highest proportion of mild cases was in young patients aged between 18 and 29 years (P < 0.05). The majority of patients presented general symptoms and signs before hospital; only one‐third had neurological symptoms and signs (Table 1). Neurological symptoms and signs are presented in Table 2. Limb paresis appeared on average on the 10th day of the illness, range eighth to 15th day.
Table 2

Clinical presentation of central nervous system involvement (n = 712)

Symptoms and signs n (%)Duration of resolved symptoms, mean (max–min) (days)Not resolved cases (%)
Meningeal signs
Overall474 (66.5)4.57 (<1–32)2/474 (0.4)
Neck stiffness442 (62.1)4.3 (<1–22)2/442 (0.5)
Kernig's sign331 (46.5)4.6 (<1–32)2/331 (0.6)
Ataxia579 (81.3)7.4 (<1–37)323/579 (55.3)
Tremor338 (47.5)6.2 (<1–42)163/338 (47.9)
Nystagmus219 (30.8)4.7 (<1–18)5/219 (2.3)
Epileptic seizures15 (2.1)3.25 (<1–15)0
Parkinson's syndrome11 (1.5)7.2 (2–21)4/11 (36.4)
Pyramidal signs88 (8.1)5.3 (<1–16)2/88 (2.3)
Dysphagia14 (2)3.6 (<1–12)1/14 (7.1)
Altered consciousness
Quantitative (overall)171 (24)2.7 (<1–34)3/171 (1.7)
Somnolence151 (21.2)2.1 (<1–16)2/151 (1.3)
Sopor31 (4.4)2.5 (<1–8)1/31 (3.2)
Comatose11 (1.6)5.2 (1–17)3/11 (27.3)
Qualitative (overall)105 (14.8)3/105 (2.9)
Agitation36 (5.1)1.7 (<1–10)1/36 (2.8)
Disorientation98 (13.8)3.3 (<1–40)3/98 (3)
Hallucinations7 (1)1 (<1–2)1/7 (14.3)
Cranial neuropathies (overall)159 (22.3)
Ocular motor paresis (III, IV, VI)52 (7.3)5.5 (<1–29)2/52 (3.8)
Facial weakness (VII)7 (1)4.5 (2–7)5/7 (71.4)
Hearing disturbance (VIII)16 (2.3)3 (3–3)14/16 (87.5)
Bulbar signs77 (10.8)
Dysphonia56 (7.9)8.1 (2–48)18/56 (32.1)
Dysarthria49 (6.9)8.2 (<1–48)13/49 (26.5)
Dysphagia12 (1.6)14 (2–48)7/12 (58.3)
Paresis of elevator muscles of head (XI)4 (0.6)4/4 (100)
Visual field defect (II)1 (0.1)1/1
Anosmia (I)1 (0.1)1/1
Masticatory muscle paresis (V)11/1
Limb paresis (overall)45 (6.3)31/45 (68.9)
Spastic21 (3)6.5 (<1–20)7/21 (33.3)
Flaccid (overall)24 (3.4)24/24 (100)
Tetraparesis10 (1)10/10 (100)
Clinical presentation of central nervous system involvement (n = 712) Coinfection with Lyme borreliosis was diagnosed in 13 patients (2%). The results of logistic regression show that significant prognostic factors for a severe case of the disease are age above 61 [adjusted odds ratio (ORa) 2.10, 95% confidence interval 1.04–3.73] and delayed immune response of specific IgG (ORa 2.37, 95% confidence interval 1.05–5.39) (Table 3).
Table 3

Prognostic factors for severe disease

VariableORc ORa 95% CI P
Sex
Female1.01.00.27
Male1.151.270.84–1.92
Age group (years)
<401.0
41–601.351.440.82–2.550.20
61+2.242.101.04–3.730.036
Comorbidities
01.01.0
11.741.450.86–2.430.16
22.221.910.97–3.760.06
32.662.431.02–5.780.044
4+3.152.050.72–5.840.18
Delayed hospitalization
0–5 days1.01.0
6+0.93.710.45–1.120.14
Cytosis
<5001.001.01.0
500+2.772.520.93–6.810.07
Delayed immune response
(IgM+, IgG−)3.272.371.05–5.390.04

N = 645. CI, confidence interval; ORc, crude odds ratio; ORa, adjusted odds ratio. Likelihood ratio χ 2 = 42.50, df 11, P < 0.0001. Hosmer–Lemeshow test χ2 = 5.99, df 8, P = 0.65. McFadden's R 2 = 0.068, model correctly classified 81.71%, area under the receiver operating curve 0.67.

Prognostic factors for severe disease N = 645. CI, confidence interval; ORc, crude odds ratio; ORa, adjusted odds ratio. Likelihood ratio χ 2 = 42.50, df 11, P < 0.0001. Hosmer–Lemeshow test χ2 = 5.99, df 8, P = 0.65. McFadden's R 2 = 0.068, model correctly classified 81.71%, area under the receiver operating curve 0.67.

Laboratory findings

Cerebrospinal fluid analyses were performed for 684/712 (96.1%) patients. Cytosis above 5 × 106 cells/l was found in 642 (93.8%) patients (mean 137.3, minimum 6, maximum 1381). The mean concentration of protein was 0.83 mg/l (minimum 0.13, maximum 6.23). The mean glucose/blood ratio was 0.57 mmol/l (minimum 0.07, maximum 1.25). The rate of seroprevalence of B. burgdorferi IgM was 18.5% in 271 patients without any symptoms and signs of borreliosis; B. burgdorferi IgG antibodies were detected in 60 (22.5%) of 267 examined patients. Computer tomography (CT) abnormalities were found in 16/148 (10.8%) patients. Brain magnetic resonance imaging (MRI) abnormalities were found in 10/63 (15.9%) examined patients. Hyperintensities of white matter and cortex (thalamus, basal ganglia, cerebellum, mesencephalon and pontine) were revealed in T2 sequence (Fig. S1). Spinal CT and MRI did not present any specific findings. Electroencephalography was done for 13 patients. Abnormalities were found in 10 patients. Non‐specific findings were found.

Complications and outcome

The complication rate was 25/712 (3.5%). The most common complication was ventilation associated pneumonia (7, 1%). Other complications included sepsis caused by Escherichia coli, Gemella morbillorum cases, septic endocarditis caused by Staphylococcus aureus (one case), urinary tract infection (three cases), exacerbation of coronary heart disease (two cases), atrial fibrillation (two cases), gastrointestinal bleeding (one case), methroragia (one case), epistaxis (one case), thrombosis sinus sagittalis (one case). A total of 11 (1.5%) patients needed mechanical ventilation, which lasted on average 7.4 days. Respiratory failure due to myelitis was presented on discharge for four patients. A total of 5/712 (0.7%) patients died. A total of 544 patients (76.7%) were discharged with sequelae. The most common persisting general symptoms on discharge were general malaise (333, 47%) and vertigo (232, 32.7%). The most frequent neurological signs were ataxia (320, 45%) and tremor (162, 22.8%). Cognitive disorders were observed in 30 (4.2%) cases. A total of 288 (40.6%) patients needed rehabilitation.

Discussion

Tick‐borne diseases are the most common vector‐borne diseases in Europe, with their infection rate and geographical distribution increasing in the 1980s 6. The apparent increase in the incidence of TBE has been attributed to global warming and various socioeconomic factors 7. The highest incidence (>10 cases per 100 000 population) is registered in the Baltic countries, the Czech Republic, Russia and Slovenia 2. Important changes in TBE were observed in Lithuania in 1991 and 1994, followed by high incidence rates and some fluctuations every year. A complex of factors influenced changes in the TBE situation in Lithuania. The abundance of ticks, climatic and social factors, better laboratory diagnostics and the possible influence of a transitional period were analysed and had an impact on the situation 8. The observed changes in spatial distribution during the period 2005–2014 showed a significant increase of TBE in areas with previously low incidence in eastern and eastern northern parts of Lithuania. The rise of new foci or the spread of old ones could be reasons for this geographical spread, but a more detailed analysis is needed. The age and gender distribution of TBE was consistent with the situation in other EU countries 9. The seasonal distribution in Lithuania is specific and different from the EU. An increase in cases in Lithuania started in April, as in other EU countries. However, a peak was observed in October in Lithuania during 2005–2014, whilst the EU reported a peak in July and a slow decrease for the rest of the year in 2012–2014 9. The highest proportion of patients with meningoencephalitis (81%) was found compared with previous studies 10, 11. Surprisingly, the rate of patients with meningitis was significantly lower in our study 11, 12. One explanation could be that meningitis forms are undiagnosed, especially if patients present only general symptoms and signs. Another explanation could be related to virus virulence. In Lithuania, the western subtype, which causes milder diseases than the other two subtypes, is prevalent. Research into ticks and TBEV is needed in order to investigate possible changes in TBEV virulence, new foci and new subtypes. The most common neurological signs were ataxia and tremor, as in previous studies, but the proportions of these signs were higher in our study 10, 11, 13. Monophasic disease and increasing age were found to correlate with the severity of the illness. These findings were also proved by other authors 10, 12. Contrary to another study 12, it was found that a CSF leukocyte count above 500 is a predictor for severe illness. In the study by Czupryna et al. 14, MRI abnormalities are present in only approximately 18% of patients. They are non‐specific, and most commonly located in the thalamus, cerebellum, brainstem and in the basal ganglia. Abnormalities in the same localization were found in 16% of examined patients in our study. Factors such as prolonged hospitalization, long‐lasting rehabilitation and loss of working ability are associated with significant social economic loss. The incidence of TBE is very high in Lithuania, but vaccination coverage is still low, especially in the at‐risk group. Vaccination would significantly reduce the negative socioeconomic impact of TBE. TBE vaccines in general have been proved to be highly immunogenic and safe 3. TBE needs to become an important issue in travel medicine 3, 15.

Conclusions

The incidence of TBE has fluctuated considerably from year to year and has significantly increased since 1992. During the high incidence period of the last two decades, there was no significant change in the incidence trend, but changes in spatial distribution were observed. Intensified efforts in promoting TBE vaccination will be needed in the light of the high incidence and expanded spatial distribution. The most common symptoms and signs of TBE were fever, headache and cerebellar signs. More patients presented only general symptoms and signs than neurological in the first week of the illness. One‐fifth of patients had a life‐threatening severe form of illness. Significant prognostic factors for severe cases of the disease were age above 61 and delayed immune response of specific IgG.

Disclosure of conflicts of interest

The authors declare no financial or other conflicts of interest. Figure S1. Brain MRI of patient with tick‐borne encephalitis (TBE). Hyperintensities: (a) in cerebellum; (b) in the basal ganglia and thalamus; (c) in subcortical white matter. Click here for additional data file.
  12 in total

1.  Permutation tests for joinpoint regression with applications to cancer rates.

Authors:  H J Kim; M P Fay; E J Feuer; D N Midthune
Journal:  Stat Med       Date:  2000-02-15       Impact factor: 2.373

2.  Tick-borne encephalitis: a disease neglected by travel medicine.

Authors:  Martin Haditsch; Ursula Kunze
Journal:  Travel Med Infect Dis       Date:  2013-07-31       Impact factor: 6.211

3.  Tick-borne encephalitis in Latvia 1973-2009: epidemiology, clinical features and sequelae.

Authors:  G Karelis; A Bormane; I Logina; I Lucenko; N Suna; A Krumina; M Donaghy
Journal:  Eur J Neurol       Date:  2011-05-25       Impact factor: 6.089

4.  Increasing incidence of tick-borne encephalitis and its importance in the Slovak Republic.

Authors:  Erik Dorko; Kvetoslava Rimárová; Peter Kizek; Milan Stebnický; L'ubica Zákutná
Journal:  Cent Eur J Public Health       Date:  2014-12       Impact factor: 1.163

5.  Tick-borne encephalitis in Poland in years 1993-2008--epidemiology and clinical presentation. A retrospective study of 687 patients.

Authors:  P Czupryna; A Moniuszko; S A Pancewicz; S Grygorczuk; M Kondrusik; J Zajkowska
Journal:  Eur J Neurol       Date:  2010-12-12       Impact factor: 6.089

Review 6.  Tick-borne encephalitis 2010: epidemiology, risk areas, and virus strains in Europe and Asia-an overview.

Authors:  Jochen Süss
Journal:  Ticks Tick Borne Dis       Date:  2010-12-17       Impact factor: 3.744

7.  Tickborne encephalitis in an area of high endemicity in lithuania: disease severity and long-term prognosis.

Authors:  Aukse Mickiene; Alvydas Laiskonis; Göran Günther; Sirkka Vene; Ake Lundkvist; Lars Lindquist
Journal:  Clin Infect Dis       Date:  2002-08-20       Impact factor: 9.079

8.  Tick-borne encephalitis-still on the map: Report of the 18th annual meeting of the international scientific working group on tick-borne encephalitis (ISW-TBE).

Authors:  Ursula Kunze
Journal:  Ticks Tick Borne Dis       Date:  2016-05-06       Impact factor: 3.744

9.  MRI and planimetric CT follow-up study of patients with severe tick-borne encephalitis.

Authors:  Piotr Czupryna; Eugeniusz Tarasow; Anna Moniuszko-Malinowska; Sławomir Pancewicz; Olga Zajkowska; Arkadiusz Targoński; Monika Chorąży; Krzysztof Rutkowski; Justyna Dunaj; Sambor Grygorczuk; Maciej Kondrusik; Joanna Zajkowska
Journal:  Infect Dis (Lond)       Date:  2016

10.  Climate change cannot explain the upsurge of tick-borne encephalitis in the Baltics.

Authors:  Dana Sumilo; Loreta Asokliene; Antra Bormane; Veera Vasilenko; Irina Golovljova; Sarah E Randolph
Journal:  PLoS One       Date:  2007-06-06       Impact factor: 3.240

View more
  13 in total

1.  Exome-wide search and functional annotation of genes associated in patients with severe tick-borne encephalitis in a Russian population.

Authors:  Elena V Ignatieva; Andrey A Yurchenko; Mikhail I Voevoda; Nikolay S Yudin
Journal:  BMC Med Genomics       Date:  2019-05-24       Impact factor: 3.063

Review 2.  Epidemiological Trends of Trans-Boundary Tick-Borne Encephalitis in Europe, 2000-2019.

Authors:  Mulugeta A Wondim; Piotr Czupryna; Sławomir Pancewicz; Ewelina Kruszewska; Monika Groth; Anna Moniuszko-Malinowska
Journal:  Pathogens       Date:  2022-06-18

3.  Tick-borne encephalitis in Europe, 2012 to 2016.

Authors:  Julien Beauté; Gianfranco Spiteri; Eva Warns-Petit; Hervé Zeller
Journal:  Euro Surveill       Date:  2018-11

4.  Cross-Sectional Study on the Prevalence and Factors Influencing Occurrence of Tick-Borne Encephalitis in Horses in Lithuania.

Authors:  Arnoldas Pautienius; Austeja Armonaite; Evelina Simkute; Ruta Zagrabskaite; Jurate Buitkuviene; Russell Alpizar-Jara; Juozas Grigas; Indre Zakiene; Dainius Zienius; Algirdas Salomskas; Arunas Stankevicius
Journal:  Pathogens       Date:  2021-01-31

5.  Lyme Disease among Patients at an Ambulatory Unit in a Highly Endemic Country: Lithuania.

Authors:  Agnė Petrulionienė; Daiva Radzišauskienė; Algimantas Paulauskas; Algirdas Venalis
Journal:  Medicina (Kaunas)       Date:  2021-02-21       Impact factor: 2.430

6.  Incidence of Tick-Borne Encephalitis during the COVID-19 Pandemic in Selected European Countries.

Authors:  Zbigniew Zając; Katarzyna Bartosik; Joanna Kulisz; Aneta Woźniak
Journal:  J Clin Med       Date:  2022-02-02       Impact factor: 4.241

Review 7.  Food-Borne Transmission of Tick-Borne Encephalitis Virus-Spread, Consequences, and Prophylaxis.

Authors:  Alicja M Buczek; Weronika Buczek; Alicja Buczek; Joanna Wysokińska-Miszczuk
Journal:  Int J Environ Res Public Health       Date:  2022-02-05       Impact factor: 3.390

8.  Epidemiology of Lyme Disease in a Highly Endemic European Zone.

Authors:  Agnė Petrulionienė; Daiva Radzišauskienė; Arvydas Ambrozaitis; Saulius Čaplinskas; Algimantas Paulauskas; Algirdas Venalis
Journal:  Medicina (Kaunas)       Date:  2020-03-05       Impact factor: 2.430

9.  Clinical Characteristics of Patients with Tick-Borne Encephalitis (TBE): A European Multicentre Study from 2010 to 2017.

Authors:  Benno Kohlmaier; Nina A Schweintzger; Manfred G Sagmeister; Vendula Švendová; Daniela S Kohlfürst; Astrid Sonnleitner; Manuel Leitner; Andrea Berghold; Erich Schmiedberger; Franz Fazekas; Alexander Pichler; Jana Rejc-Marko; Daniel Růžek; Lucie Dufková; Darina Čejková; Petr Husa; Martina Pýchová; Lenka Krbková; Václav Chmelík; Věra Štruncová; Dace Zavadska; Guntis Karelis; Aukse Mickiene; Joanna Zajkowska; Petra Bogovič; Franc Strle; Werner Zenz
Journal:  Microorganisms       Date:  2021-06-30

10.  Bulk Milk Tank Samples Are Suitable to Assess Circulation of Tick-Borne Encephalitis Virus in High Endemic Areas.

Authors:  Arnoldas Pautienius; Gytis Dudas; Evelina Simkute; Juozas Grigas; Indre Zakiene; Algimantas Paulauskas; Austeja Armonaite; Dainius Zienius; Evaldas Slyzius; Arunas Stankevicius
Journal:  Viruses       Date:  2021-09-05       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.